Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced that it has successfully developed a scalable process, with demonstrated production at 500 litre scale, for producing cannabigerol (“CBG”) with greater than 99% purity and no detectable tetrahydrocannabinol (“THC”). “Achieving scalable production of pure CBG … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Achieves Scalable Production of Pure CBG”
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced that its president and CEO, Trevor Peters, will present live at LifeSciencesInvestorForum.com at 2:30 p.m. ET on September 17, 2020. Interested parties may register for and access the presentation at http://cnw.fm/aTrB8. Investors are invited to … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Webcast Live at Life Sciences Investor Forum”
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), today announced that its subsidiary, Willow Analytics Inc., will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) supporting a research and development project to advance production of its varin cannabinoids using its proprietary biosynthetic platform. “We welcome the … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Receive Advisory Services, Funding for Rare Cannabinoid Development Platform”
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) this morning announced that it has been approved to commence trading on the OTCQX(R) Best Market (the “OTCQX”) under the symbol “CANSF,” beginning today, July 22, 2020. Willow has upgraded to the OTCQX from the OTCQB(R) Venture Market (the “OTCQB”). “We are very excited to migrate to the top … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Moves to the Top of the OTC Market”
Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical grade quality cannabinoids via synthetic biology, today announced that its CEO and President Trevor Peters will present live at VirtualInvestorConferences.com at 12:00 p.m. Eastern Time on Thursday, July 9. Interested parties are encouraged to visit www.VirtualInvestorConferences.com to pre-register and run the … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) to Present at VirtualInvestorConferences.com”
Willow Biosciences (TSX: WLLW) (OTCQB: CANSF) on Monday announced that Christopher Speed has joined the Company as Senior Vice President, Sales and Marketing, effective July 1, 2020. In this role, Speed will be responsible for leading the sales and marketing of Willow’s new line of cannabinoids, along with the Company’s strategic planning and customer initiatives. … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) Appoints New SVP to Lead Sales and Marketing of New Line of Cannabinoids”
Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), a Canadian biotechnology company creating high purity, plant-derived compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries, today announced further acceleration of its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. “Willow’s scientific and operational success … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) Announces Further Acceleration of Path to Commercialization, Expands Portfolio”
Willow Biosciences (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, is well positioned to disrupt the cannabis industry supply chain by utilizing its ability to provide biosynthetically derived cannabinoids. A recent article discussing the company reads, “Willow ultimately intends to biosynthetically produce a variety of cannabinoids using biosynthesis, … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Holds Potential to Supply Biosynthetically Derived Cannabinoids”
Willow Biosciences (CSE: WLLW) (OTCQB: CANSF) on Tuesday announced its receipt of final approval to list its common shares on the Toronto Stock Exchange (the “TSX”). According to the update, Willow’s common shares will commence trading on the TSX effective as of the open of the market on Thursday, December 5, 2019. The common shares … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) to Commence Trading on the Toronto Stock Exchange on December 5”
Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), a Canadian biotechnology company and a leading developer in biosynthetically produced cannabidiol (“CBD”), this morning issued a release commenting on the recent news that the U.S. Drug Enforcement Agency (“DEA”) has removed Purisys, LLC’s CBD from Schedule I of the Controlled Substances Act (“CSA”). Purisys, the spin-out entity … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Comments on DEA Descheduling Partner’s CBD”
